Erratum: Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer (Cancer Research (2019) 79 (2580–2592) DOI: 10.1158/0008-5472.CAN-18-2812)

Shangze Li, Ka Wing Fong, Galina Gritsina, Ali Zhang, Jonathan C. Zhao, Jung Kim, Adam Sharp, Wei Yuan, Caterina Aversa, Ximing J. Yang, Peter S. Nelson, Felix Y. Feng, Arul M. Chinnaiyan, Johann S. de Bono, Colm Morrissey, Matthew B. Rettig, Jindan Yu

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original version of this article (1), the same image was inadvertently duplicated in Fig. 5J, column #2. These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.

Original languageEnglish (US)
Pages (from-to)2072
Number of pages1
JournalCancer Research
Volume80
Issue number10
DOIs
StatePublished - May 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erratum: Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer (Cancer Research (2019) 79 (2580–2592) DOI: 10.1158/0008-5472.CAN-18-2812)'. Together they form a unique fingerprint.

Cite this